SeekingAlpha · Aug 11, 2026
AngioDynamics, Inc. (ANGO) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow
2026-08-11. The following slide deck was published by AngioDynamics, Inc.
AN
NASDAQ · ANGO
AngioDynamics, Inc.
Healthcare · Medical - Instruments & Supplies
$15.75
Down-$0.07 (-0.44%)
Updated Aug 23, 2026, 12:39 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 471.53M
- P/E ratio
- -17.09
- Dividend yield
- 0.00%
- 52-week range
- $9.39 – $16.29
- Volume
- 150.07K
- Avg. volume
- 570.39K
Price performance
ANGO price history
1M range · 20 trading sessions · Daily adjusted prices
ANGO closed at $15.75 after 20 trading sessions, up 15.30% for the selected period.
- Last close
- $15.75
- Period change
- +15.30%
- Period low
- $13.66
- Period high
- $16.07
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $15.85 | $15.85 | $15.6001 | $15.75 | 150.07K |
| Aug 20, 2026 | $15.67 | $16.155 | $15.67 | $15.82 | 160.69K |
| Aug 19, 2026 | $16.06 | $16.29 | $15.8301 | $16.07 | 305.5K |
| Aug 18, 2026 | $15.68 | $16.05 | $15.475 | $15.82 | 335.66K |
| Aug 17, 2026 | $15.38 | $15.74 | $15.27 | $15.67 | 304.58K |
| Aug 14, 2026 | $15.71 | $15.94 | $15.545 | $15.85 | 330.04K |
| Aug 13, 2026 | $15.97 | $16.04 | $15.45 | $15.66 | 409.43K |
| Aug 12, 2026 | $15.80 | $15.89 | $15.22 | $15.75 | 787.47K |
| Aug 11, 2026 | $15.78 | $16.11 | $15.69 | $15.75 | 839.07K |
| Aug 10, 2026 | $15.55 | $16.05 | $15.41 | $15.75 | 521.2K |
| Aug 7, 2026 | $15.16 | $15.73 | $15.14 | $15.69 | 405.99K |
| Aug 6, 2026 | $15.11 | $15.29 | $14.95 | $15.11 | 357.42K |
| Aug 5, 2026 | $15.27 | $15.27 | $14.83 | $15.04 | 538.44K |
| Aug 4, 2026 | $15.16 | $15.25 | $14.915 | $15.19 | 624.11K |
| Aug 3, 2026 | $14.79 | $15.41 | $14.79 | $15.17 | 774.02K |
| Jul 31, 2026 | $14.75 | $14.93 | $14.59 | $14.79 | 467.59K |
| Jul 30, 2026 | $14.65 | $14.81 | $14.3521 | $14.77 | 399.1K |
| Jul 29, 2026 | $14.25 | $14.68 | $14.25 | $14.63 | 434.57K |
| Jul 28, 2026 | $13.87 | $14.55 | $13.87 | $14.34 | 514.83K |
| Jul 27, 2026 | $13.65 | $14.005 | $13.64 | $13.66 | 403.1K |
Latest ANGO news
The latest Smart Investors Daily articles mentioning ANGO.
Stock researchCompany · Overview
ANGO research
Overview
Company profile and research snapshot.
Company profile
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $18.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 15, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 15, 2026 | Canaccord Genuity | Buy | — |
| Apr 6, 2026 | Freedom Broker | Buy | — |
| Apr 6, 2026 | Canaccord Genuity | Buy | — |
| Oct 3, 2025 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 6, 2026
Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.
Yahoo · Aug 6, 2026
ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus
AngioDynamics' fiscal 2027 outlook hinges on Med Tech growth offsetting flat device sales as tariffs, spending and losses pressure margins.
Yahoo · Aug 6, 2026
ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?
AngioDynamics' 33.5% three-month rally rests on Med Tech growth, but valuation, tariffs and negative earnings keep execution risks high.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
